HC Wainwright & Co. Maintains Buy on Revance Therapeutics, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao maintains a 'Buy' rating on Revance Therapeutics (NASDAQ:RVNC) but has lowered the price target from $41 to $15.
November 06, 2023 | 11:38 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Revance Therapeutics' price target has been lowered from $41 to $15 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target for Revance Therapeutics by HC Wainwright & Co. could potentially lead to a decrease in the stock's price in the short term. However, the maintenance of the 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100